- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose)
- Biological · Other
- Lead sponsor
- Meissa Vaccines, Inc.
- Industry
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 265
matching trials from the live ClinicalTrials.gov search.
- Conditions
- RSV Infection
- Interventions
- Candidate vaccine, SCB-1019T, AREXVY, placebo
- Biological · Other
- Lead sponsor
- Clover Biopharmaceuticals USA, LLC
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Fort Myers, Florida • Lexington, Kentucky + 2 more
- Conditions
- RSV
- Interventions
- RSVpreF (Group 1), RSVpreF (Group 2), RSVpreF (Group 3), Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 1,028 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 18
- States / cities
- Miami Lakes, Florida • Sunrise, Florida • Winter Park, Florida + 13 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- S-337395, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 37
- States / cities
- Los Angeles, California • Modesto, California • Toluca Lake, California + 23 more
- Conditions
- Infection
- Interventions
- ribavirin
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 2 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Chicago, Illinois • St Louis, Missouri + 1 more
- Conditions
- Upper Respiratory Tract Infection, Lower Respiratory Tract Infection
- Interventions
- RI-001
- Biological
- Lead sponsor
- ADMA Biologics, Inc.
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 15
- States / cities
- San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
- Conditions
- Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia, Cancer, Acute Leukemia
- Interventions
- Ribavirin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 11
- States / cities
- Denver, Colorado • Hialeah, Florida • Savannah, Georgia + 8 more
- Conditions
- Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
- Interventions
- RSV preF-based Vaccine, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 11
- States / cities
- Long Beach, California • DeLand, Florida • Miami Lakes, Florida + 7 more
- Conditions
- Respiratory Syncytial Virus Infections+Metapneumovirus
- Interventions
- RSV/hMPV_V low dose vaccine, RSV/hMPV_V medium dose vaccine, RSV/hMPV_V high dose vaccine, RSV/hMPV_W low dose vaccine, RSV/hMPV_W medium dose vaccine, RSV/hMPV_W high dose vaccine, RSV/hMPV_X low dose vaccine, RSV/hMPV_X medium dose vaccine, RSV/hMPV_X high dose vaccine, hMPV_Y low dose vaccine, hMPV_Y medium dose vaccine, hMPV_Y high dose vaccine, hMPV_Z low dose vaccine, hMPV_Z medium dose vaccine, hMPV_Z high dose vaccine, Control vaccine, Placebo
- Biological · Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,456 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Stockbridge, Georgia • Lenexa, Kansas • Seattle, Washington
- Conditions
- Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
- Interventions
- Placebo, SeVRSV Vaccine
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV cps2 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Laurel, Maryland
- Conditions
- RSV Infection
- Interventions
- EDP-938, Fluconazole
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Healthy
- Interventions
- MEDI-534
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 1 Year to 9 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 12
- States / cities
- Fountain Valley, California • Shawnee, Kansas • Topeka, Kansas + 9 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV-F Vaccine, Phosphate Buffer Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 11,850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 51 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 1,586 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- Up to 6 Months
- Enrollment
- 1,177 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more
- Conditions
- Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
- Interventions
- RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1
- Biological · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 50
- States / cities
- Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- ALN-RSV01, Normal Saline
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Abrysvo, Beyfortus
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 181 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • New York, New York + 5 more
- Conditions
- RSV Infection
- Interventions
- EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Respiratory Infections, Bronchiolitis, Pneumonia, Apnea
- Interventions
- Emergency Dept. Subjects with LRI or Apnea
- Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 1 Day to 12 Months
- Enrollment
- 2,048 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Sylmar, California • Denver, Colorado + 29 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSVpreF (Regimen A), RSVpreF (Regimen B)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 13
- States / cities
- Tempe, Arizona • Dublin, California • Doral, Florida + 10 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more